ISHLT2025: Industry Symposia - Sunday

CareDx

HeartCare in 2025: Is Molecular Multi-Modality the Secret to the Liquid Biopsy?

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

This session will be an interactive case discussion describing rational and evidence-based HeartCare interpretation as it relates to all aspects of cardiac transplant surveillance. Multiple clinical scenarios and timepoints will be included in this discussion identifying risk of ACR and or AMR and potential clinical care plans.

Moderator

Jeremy Kobulnik, MD, MHSc, CareDx, Brisbane, CA USA

Speakers

Ersilia DeFilippis, MD, FACC, FHFSA, New York Presbyterian / Columbia University Irving Medical Center, New York, NY USA
Marcus Anthony Urey, MD, University of California San Diego, San Diego, CA USA
Luise Holzhauser, MD, University of Pennsylvania, Philadelphia, PA USA
Benjamin Mackie, MD, Tampa General Hospital, Tampa, FL USA

Johnson & Johnson MedTech | Heart Recovery

Advancing the Science of Heart Recovery: Lessons Learned from SURPASS Study and DanGer Shock Trial

Primary Core Therapy: Heart | Primary Practice Area: Cardiology

Join our expert panel as they delve into the findings from the recent SURPASS Study featuring the Impella 5.5® with SmartAssist®, alongside the transformative DanGer Shock Trial. Our discussions will focus on effectively applying the insights gained from the DanGer Shock Trial for AMI-CS to enhance the management of HF-CS. Attendees will uncover innovative strategies for seamlessly integrating the science of heart recovery into clinical best practices. Be part of this vital conversation and contribute to shaping the future of cardiac care!

Moderator

Navin Kapur, MD, Tufts Medical Center, Boston, MA USA

Program

Lessons Learned from SURPASS Study with Impella 5.5

David D'Alessandro, MD, Massachsetts General Hospital / Harvard Medical School, Boston, MA USA

Insights Gained from the DanGer Shock Trial for AMI-CS to Enhance the Management of HF-CS

Jacob Møller, MD, Odense University Hosiptal, Odense, Denmarck

Considerations for the INTeGRATE Study Design

Marwan Jumean, MD, UT Health, Houston, TX USA

Best Practices with Impella 5.5

Manreet Kanwar, MD, University of Chicago, Chicago, IL USA

Lung Bioengineering

The Pros, The Cons, The Wicked Good EVLP Debates

This session will include two separate pro and con debates. The first debate will be pros and cons of the centralized EVLP model. The second debate will be the pros and cons of extended CIT2 post-EVLP and transplant outcomes.

ModeratorS

Caitlin Demarest, MD, PhD, Vanderbilt University Medical Center, Nashville, TN USA
Jacob Klapper, MD, FACS, Duke University Medical Center, Raleigh, NC USA

Program

Using a Centralized EVLP Model (PRO)

Sravanthi Nandavaram, MD, FCCP, Massachusetts General Hospital, Boston, MA USA

Using a Centraliezed EVLP Model (CON)

Pedro Catarino, MD, Cedars Sinai, West Hollywood, CA USA

Rebuttal (PRO)

Sravanthi Nandavaram, MD, FCCP, Massachusetts General Hospital, Boston, MA USA

Rebuttal (CON)

Pedro Catarino, MD, Cedars Sinai, West Hollywood, CA USA

Using Extended CIT2 Post-EVLP (PRO)

Jasleen Kukreja, MD, MPH, University of California San Francisco, San Francisco, CA USA

Using Extended CIT2 Post-EVLP (CON)

Mani Daneshmand, MD, Emory University, Atlanta, GA USA

Rebuttal (PRO)

Jasleen Kukreja, MD, MPH, University of California San Francisco, San Francisco, CA USA

Rebuttal (CON)

Mani Daneshmand, MD, Emory University, Atlanta, GA USA

Natera

Expanding Our Understanding of dd-cfDNA in providing Lung Transplant Personalized Care

Primary Core Therapy: Lung | Primary Practice Area: Pulmonology

This symposium will provide a brief history of dd-cfDNA in lung transplantation rejection monitoring, highlighting the power of the negative to rule out rejection. Understandably, elevated dd-cfDNA% results are more common in lung than other solid organ transplant due to the nature of detecting tissue damage or injury. Infection is a common cause for elevated results in lung, but elevated Prospera Lung tests may also lead to important clinical insights for complex patients. This interactive session will also explore clinical case studies where elevated Prospera results led to key clinical insights for patients to better their care.

Moderator

Justin Rosenheck, DO, The Ohio State University Wexner Medical Center, Columbus, OH USA

Program

Introduction

Justin Rosenheck, DO, The Ohio State University Wexner Medical Center, Columbus, OH USA

Prospera Lung Case Studies

Samir Sultan, DO, MS, Medical College of Wisconsin, Milwaukee, WI USA

Prospera Lung Case Studies

Irina Timofte, MD, MS, UT Southwestern Medical Center, Dallas, TX USA

The Future of dd-cfDNA

Sangeeta Bhorade, MD, Natera, Chicago, IL USA

XVIVO

New HOPE for Hearts: It's About Time

Primary Core Therapy: Heart | Primary Practice Area: Cardiothoracic Surgery

Hypothermic oxygenated perfusion is changing the paradigm of heart preservation: enabling extended preservation times, improving patient outcomes, and increasing heart utilization. Join us for an inspiring symposium, where we will reveal 1-year data from the European randomized controlled trial. We will also discuss the impact of HOPE through clinical experiences and outcomes, including DCD insights from both Europe and the U.S.

Moderators

Göran Dellgren, MD, PhD, Sahlgrenska University Hospital, Göteborg, Sweden, Sweden
Victor Pretorius, MBchB, FRCS, University of California San Diego, San Diego, CA USA

Program

Hypothermic Oxygenated Perfusion (HOPE)

Andreas Wallinder, MD, XVIVO Perfusion AB, Mölndal, Sweden

1-year Data from the NIHP 2019 Trial and DCD Cases in Leuven

Filip Rega, MD, PhD, University Hospitals Leuven, Leuven, Begium

PRESERVE Heart Trial: The Vanderbilt DCD Experience

Ash Shah, MD, Vanderbilt University Medical Center, Nashville, TN USA